Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer
Authors:
Open Access
- 16 June 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 8 (8) , 1128-1136
Abstract
Prostate cancer is the most commonly diagnosed cancer in men in the US,1 with approximately 70% of patients with a new diagnosis having localized disease.2 Based on National Comprehensive Cancer Network treatment guidelines, active surveillance (AS) is a recommended management option for patients with clinically localized very low-risk, low-risk, or intermediate-risk prostate cancer.3 Patients who are undergoing or are eligible to undergo AS who opt for treatment with a definitive therapy, such as radical prostatectomy, external beam radiation therapy, or brachytherapy, may experience adverse effects, including sexual and voiding dysfunction.3 The decision for treatment intervention is influenced by various factors, including pathological upgrading of disease, grade reclassification, and patient well-being. Biopsy type may influence disease assessment, with some studies showing an exclusion of men from AS protocols because of disease reclassification following a multiparametric magnetic resonance imaging (mpMRI)–targeted biopsy.4Keywords
This publication has 11 references indexed in Scilit:
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate CancerJournal of Clinical Oncology, 2019
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerNew England Journal of Medicine, 2019
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerNew England Journal of Medicine, 2018
- Neoadjuvant Enzalutamide Prior to ProstatectomyClinical Cancer Research, 2017
- Faculty Opinions recommendation of Increased survival with enzalutamide in prostate cancer after chemotherapy.2016
- Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up ResultsEuropean Urology, 2015
- Targeted Prostate Biopsy to Select Men for Active Surveillance: Do the Epstein Criteria Still Apply?Journal of Urology, 2014
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trialThe Lancet, 2012